Company Profile

Description
NeuroSearch is a biopharmaceutical company specializing in central nervous diseases (CNS). The company has two businesses: Specialty Pharma, focusing on completing the development and marketing of their first product; Huntexil against Huntington's disease. The second business NsDiscovery, manages early drug discoveries. The drug Tesofensine against obesity is also ready for clinical phase III and NeuroSearch seeks a partner for completion of development. Main risk factor for drug development is financial risk. The company has several drug discovery- and development collaborations with major pharmaceutical companies such as Abbott, Eli Lilly and Janssen Pharmaceuticals. The cooperation entitles NeuroSearch to premarketing milestone payments on each compound developed and potentially royalties if the drug is commercialized.
Key Stats
Website: http://www.neurosearch.com
Headquarter country: Denmark
Employees: 24
Market Cap (at close 24/09/2018): DKK 111M
Fiscal Year Ends: December

Stats



Price/Earnings
Forward Price/Earnings
Price/Free Cash Flow
Return of Assets
Return on Equity
Return on Invested Capital
20172016201520142013

5.300.6000.500 1.301.10 1.201.10 -10.3028.90-6.80-8.808.20 -10.9031.70-7.40-9.3014.60 -10.4032.30-7.20-7.209.10

Dividend


Dividend/Share


Ex. Dividend Date
Trailing Dividend Yield
Payout Ratio




01/01/0001

0.00
Date Currency Amount

Income Statement


Revenue
Total Revenue
Gross Profit
Gross Margin %
EBITDA
Net Income
Basic Earnings Per Share

Operating Expenses
Operating Income
Operation Margin %
20172016201520142013

0.000.000.000.0029.00 0.030 %%%%100.00% -10.0022.00-7.00-9.00-10.00 -8.0023.00-6.00-8.0012.00 -0.320


0.930


-0.230


-0.320


0.500


0.000.0100.0100.0100.040 0.00-0.010-0.010-0.010-0.010 %



%



%



%



-33.44%



Cash Flow


Operating Cash Flow
Operating Cash Flow
Capital Expenditures
Free Cash Flow
20172016201520142013

-5.00-3.00-5.00-8.00-18.00 -5.00-3.00-5.00-8.00-18.00

Balance Sheet



Assets
Current Assets
Long Term Assets
Total Assets

Liabilities
Total Current Liabilities
Long Term Liabilities
Total Liabilities

Equity
Retained Earnings
Treasury Stock
Total Stockholder Equity
Net Tangible Assets
31/12/201731/12/201631/12/201531/12/201431/12/2013


74,53074,92178,59484,03092,209 0.004,500.000.000.000.00 74,530




79,421




78,594




84,030




92,209




1,178.008,038.006,194.006,316.004,259.00 0.000.000.00 1,178.00




8,038.00




6,194.00














48,79856,69733,88239,42047,162 73,35271,38372,40077,71487,950 73,35271,38372,40077,71487,950

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 September 2018 20:48:39
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB4 - 2018-09-25 21:48:39 - 2018-09-25 20:48:39 - 1000 - Website: OKAY